Safety test of a new HIV vaccine in adults with or without HIV
Part of Immune system & allergy, Infections clinical trials.
This study tests a new RNA-based vaccine called BNT168 to see if it is safe and how the body responds to it. It is for healthy adults with or without HIV, and those with HIV will pause their regular treatment for a while during the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 50 years old.
- If you are HIV-negative, you need to be willing to talk about HIV risk and take steps to stay HIV-negative while in the study.
- If you are living with HIV, you must be on a stable HIV treatment for at least a year and have a healthy immune system (CD4 count >500).
- You cannot have received an HIV vaccine or certain long-acting HIV treatments before.
- You must not have serious health issues like heart disease, uncontrolled high blood pressure, diabetes, or certain immune problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
This trial tests an experimental HIV vaccine to see if it is safe and triggers an immune response. It is for healthy adults who are HIV-negative and at low risk for HIV.
This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.
This trial tests a new combination HIV vaccine in healthy adults to see if it is safe and produces an immune response. If you are at low risk for HIV, you may help researchers learn more about future prevention strategies.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.